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Abstract
Although metabolic syndrome (MS) and systemic lupus erythematosus (SLE) are often associated, a common link has not
been identified. Using the BWF1 mouse, which develops MS and SLE, we sought a molecular connection to explain the
prevalence of these two diseases in the same individuals. We determined SLE- markers (plasma anti-ds-DNA antibodies,
splenic regulatory T cells (Tregs) and cytokines, proteinuria and renal histology) and MS-markers (plasma glucose, non-
esterified fatty acids, triglycerides, insulin and leptin, liver triglycerides, visceral adipose tissue, liver and adipose tissue
expression of 86 insulin signaling-related genes) in 8-, 16-, 24-, and 36-week old BWF1 and control New-Zealand-White
female mice. Up to week 16, BWF1 mice showed MS-markers (hyperleptinemia, hyperinsulinemia, fatty liver and visceral
adipose tissue) that disappeared at week 36, when plasma anti-dsDNA antibodies, lupus nephritis and a pro-autoimmune
cytokine profile were detected. BWF1 mice had hyperleptinemia and high splenic Tregs till week 16, thereby pointing to
leptin resistance, as confirmed by the lack of increased liver P-Tyr-STAT-3. Hyperinsulinemia was associated with a down-
regulation of insulin related-genes only in adipose tissue, whereas expression of liver mammalian target of rapamicyn
(mTOR) was increased. Although leptin resistance presented early in BWF1 mice can slow-down the progression of
autoimmunity, our results suggest that sustained insulin stimulation of organs, such as liver and probably kidneys, facilitates
the over-expression and activity of mTOR and the development of SLE.
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Introduction
From the second half of the twentieth century onwards, there
has been a growth in the prevalence of two apparently unrelated
pathologic conditions, namely metabolic and autoimmune dis-
eases, especially in affluent western societies [1–5]. This occur-
rence has coincided with a drastic change in life style, involving
massive adoption of sedentary practices associated with dietary
habits skewed towards the consumption of high caloric density,
nutrient poor foods, which promote a marked positive energy
balance in the general population [6,7].
These life style changes constitute a risk factor for predisposition
to metabolic diseases (obesity, insulin resistance, metabolic
syndrome, etc.) and their cardiovascular manifestations, such as
angina pectoris and myocardial infarction [6,8]. In the past 25
years the prevalence of some of the risk factors for cardiovascular
disease (i.e. cigarette smoking, dyslipaemia, etc.) has gradually
declined; however, the prevalence of obesity, metabolic syndrome
and diabetes mellitus has dramatically increased as a result of
unhealthy changes in dietary habits and life style [3,7]. Besides,
a clear risk factor (excluding the increased concentration of
chemicals in the environment of urban areas) related to the
increased prevalence of autoimmune diseases has not been
identified to date.
Systemic lupus erythematosus (SLE) is an heterogeneous
autoimmune disease that affects multiple organs, and its highest
prevalence is reported in Italy, Spain, Martinique and the UK
Afro-Caribbean population [5,7]. The disease progresses through
four broad stages, which are in the following order: the presence of
autoantibodies against a variety of ubiquitous self-antigens; the
deposition of autoantibodies and immune complexes in tissues; the
development of tissue inflammation; and tissue damage and
fibrosis. There is a clear predominance of SLE in females, with
female-to-male ratios between 9:1 and 13:1. There has been
a marked increase in five-year survival from less than 50% in the
1950s to more than 90% in the 1990s as a result of improved
therapeutics. Those who die early in the course of SLE have active
disease and a high incidence of infection associated with treatment
with large doses of corticosteroids, while most patients who die
later in the course of the disease, the most common situation
nowadays, die from myocardial infarction [9,10].
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Patients with SLE are five to six times more likely to have
a significant coronary event than the general population [9].
Epidemiological studies point to an association of metabolic
syndrome (MS) and SLE, indicating that traditional risk factors for
cardiovascular disease clustered in the MS, such as hypertension,
insulin resistance, hepatic steatosis, diabetes mellitus and obesity,
have a significant role in the development of premature
atherosclerosis in patients with SLE [11,12]. There is growing
epidemiological evidence that obesity increases the risk of
autoimmnune diseases [13], but it is unknown whether these
pathological conditions share common molecular pathways.
The New Zealand Black (NZB) mouse is characterized by mild
SLE-like symptoms. F1 progeny from NZB mice and the non-
autoimmune New Zealand White (NZW) strain, called BWF1,
exhibit an earlier onset and a high incidence of SLE manifesta-
tions, showing many features of human SLE, including a complex
genetic origin, a bias for the female sex, immune complex
glomerulonephritis, and the presence of antinuclear antibodies
[14]. In a seminal article published by Ryan et al. [15], it was
shown that, like humans, the BWF1 mouse model presents several
characteristics of the MS, including hypertension, central obesity,
insulin resistance, hepatic steatosis and hyperleptinemia.
Here we studied the temporal evolution of SLE and MS
manifestations in the murine BWF1 model, with the aim to
identify possible molecular connections that could help to explain
the high prevalence of these two diseases in the same individuals.
We show that MS symptoms appear before those of SLE and
propose a possible interconnection of both diseases through
Figure 1. A. Bar diagram showing solid food consumption, expressed as the mean6sd of g of pelleted diet consumed per day and
animal, at different times (weeks) for control and SLE mice (8 animals per group). B. Body weight, expressed as the mean6sd in g at the
beginning of the study (week 6) and for control and SLE mice (8 animals per group) at the weeks of sacrifice. * P,0.05.
doi:10.1371/journal.pone.0051118.g001
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hyperinsulinemia and mammalian target of rapamicyn (mTOR)
up-regulation.
Materials and Methods
Animals and Experimental Design
Thirty-two female F1 progeny from New Zealand Black/White
mice characterized by SLE-like symptoms (SLE) and 32 New
Zealand White female mice used as a control (CT) were provided
by Charles River Laboratories (Barcelona, Spain). All mice were
maintained with access to water and food ad libitum and under
constant humidity and temperature with a light/dark cycle of 12
hours. After 8, 16, 24 and 36 weeks the mice were killed under
isoflurane anesthesia between 9–10 a.m. During the study, we
periodically measured solid food consumption and the body
weight.
For each group, four mice were transferred to metabolic cages
and kept 24 h for urine collection. Urinary protein excretion
(proteinuria) was determined by AlbustixR (Bayer, Barcelona,
Spain) once every 4 weeks starting from 8 week of the study,
always using the same animals.
When the animals were killed, blood was collected in 5%
EDTA-tubes for measurement of serum anti-double stranded
DNA (anti-dsDNA) antibody levels, lipids, glucose, creatinine,
insulin and leptin concentrations. Kidneys were harvested for
histological studies; spleens were also harvested and washed with
PBS-FBS 10% (10% heat inactivated fetal bovine serum) and 1%
antibiotic solution for isolation and culture of splenocytes. Hepatic
and adipose tissues were excised, weighed and immediately frozen
in liquid N2.
All procedures were conducted in accordance with the guide-
lines established by the University of Barcelona’s Bioethics
Committee, as stated in Law 5/1995 (21st July) drawn up by the
Generalitat de Catalunya.
Plasma Analysis
Blood samples were centrifuged to obtain plasma and then
stored at 220uC until needed. Plasma triglyceride, glucose
concentrations and creatinine levels were measured using the
colorimetric tests from SPINREACT (Girona, Spain) (ref.
1001312, 1001192 and K-4001, respectively). Non-esterified fatty
acids (NEFA) were measured using a colorimetric test from Wako
Chemicals GmbH (Neuss, West Germany). Plasma insulin and
leptin concentrations were determined with the Insulin RIA kit
(RI-13K) and Leptin RIA kit (RL-83K) from Linco Research
(Missouri, USA), respectively.
Plasma anti-dsDNA antibody concentration was measured by
an ELISA kit from Alpha Diagnostic International (Texas, USA),
following the manufacturer’s instructions.
Hepatic Triglyceride Contents
Liver triglyceride levels were measured as described previously
[16] and were determined using the same colorimetric test from
SPINREACT (Girona, Spain) as described above.
Fatty Acid Oxidation Activity
Hepatic fatty acid b-oxidation activity was determined as
described previously [17], using 30 mg of post nuclear supernatant
from each sample.
Western Blot Analysis
150 mg of hepatic and adipose tissue from each animal were
homogenized in a buffer containing 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Igepal, 100 mM NaF, 1 mM each of
PMSF, Nappi, sodium ortovanadate and 20 mM Tris-HCl pH 7.5
buffer to obtain the total protein fraction by centrifugation. This
fraction was stored at 280uC until needed. The protein
concentration was determined by the Bradford method [18].
30 mg of total protein (15 mg for IRS-1 experiments) were
subjected to 10% SDS-polyacrylamide gel electrophoresis. Pro-
teins were then transferred to Immobilon polyvinylidene diflouride
transfer membranes (Millipore, Bedford, MA) and blocked for 1 h
at room temperature with 5% non-fat milk solution in TBS-0.1%
Tween-20. Membranes were then incubated with the primary
polyclonal antibody raised against total-AKT, IRS-1, and RPS6K
(dilution 1:1000) in adipose tissue samples and PPARc, mTOR,
RPS6K and p-Tyr-STAT-3 (dilution 1:1000) in liver samples in
TBS-0.1% Tween-20 with 5% non-fat milk at 4uC overnight.
After several washes, the membranes were incubated with
horseradish peroxidase-conjugated anti-rabbit IgG (1:3000 dilu-
tions). Detection was achieved using the ECL chemiluminescence
kit for HRP (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).
To confirm the uniformity of protein loading in each lane, the
blots were incubated with b-actin protein. The size of the proteins
detected was estimated using protein molecular-mass standards
(BioRad Laboratories SA, Barcelona, Spain). All antibodies were
obtained from Cell Signaling Technology Inc. (Danvers, USA).
PCR- Arrays
Six total RNA pools from liver and six total RNA pools from
adipose tissue were prepared, three for CT mice and three for SLE
counterparts. Each pool was prepared with the same amount of
RNA from two mice, with a total of 6 mice in each condition.
Briefly, total RNA was isolated using TRIzol reagent (Invitrogen-
Life Technologies, New York, USA) following the manufacturer’s
instructions and was then purified using RNeasy kit columns
(Qiagen Iberia S.L., Madrid, Spain). Single stranded cDNA and
PCR arrays were performed using the RT2 ProfilerTM PCR Array
Mouse Insulin Signaling Pathway (PAMM-030A) from SaBios-
ciences (Madison, USA) and following the manufacturer’s guide-
lines. Array data processing and analysis were performed by using
a Web portal from SaBiosciences (Madison, USA).
Renal Histology
Kidney specimens were fixed in 10% formaldehyde and
embedded in paraffin. Four mm sections were stained with
haematoxylin and eosin (H&E). Inflammatory cell infiltration
and glomerular hypercellularity were evaluated semi-quantitative-
ly by a renal pathologist blinded to group assignment (arbitrary
score 0 to 3+, where 0 = no change; 1+=mid; 2+=moderate and
3+= severe).
Figure 2. A. Bar diagram showing plasma anti-ds-DNA antibody concentrations expressed as the mean6sd of 8 animals, for control
and SLE mice (8 animals per group) at the weeks of sacrifice. B–D. Percentages of CD4+- (B), CD4+CD25+- (C), and CD4+CD25+FoxP3-T cells
(D) in spleen lymphocytes, expressed as the mean6sd of 8 animals, for control and SLE mice (8 animals per group) at the weeks of sacrifice. * P,0.05,
** P,0.01.
doi:10.1371/journal.pone.0051118.g002
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Figure 3. Bar diagrams showing IL-2 (A), IL-17 (B), MCP-1 (C), IL-4 (D), IL-5 (E), IL-10 (F), IL-13 (G), M-CSF (H), TNFa (I), and VEGF (J)
concentrations in the supernatant of stimulated cultured splenocytes (see Material and Methods), expressed as the mean6sd of 8
cultures from separate animals, for control and SLE mice at week 36. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0051118.g003
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Isolation of Splenocytes
The isolated spleen from each mouse was pressed through
a sterile 40 mm nylon cell strainer (Sigma-Aldrich, St. Louis, CA,
USA) to make a single cell suspension. After centrifugation at
5386g for 10 min at 4uC, red blood cells in the pellet were lysed
by osmotic shock with PBS 1X and distilled water. In order to
restore tonicity, PBS 10X was added and the solution was vortexed
and centrifuged at 5386g for 10 min at 4uC. The pellet was then
resuspended with PBS-FBS10%. The cells were then counted and
viability was determined by the trypan blue exclusion method.
Labeling of Isolated Splenocytes and Flow Cytometry
56105 isolated spleen cells were distributed into FACS tubes
with 1 ml of PBS-FBS 2% and cold 1% NaN3. After centrifugation
at 5386g for 5 min at 4uC, the pelleted cells were resuspended and
stained with 10 ml of anti-mouse antibodies conjugated by
fluorescent dyes (mouse anti-CD4 antibody PE conjugated, mouse
anti CD25 FITC conjugated and human anti-CD7 antibody used
as a control (eBiosciences, St. Diego, CA, USA). They were then
incubated at 4uC for 20 min. After one wash with cold PBS,
stained cells were centrifuged and permeabilized using 1X
Permeabilizing Solution (ref. 00–5521, eBiosciences, St. Diego,
CA, USA) and then incubated for 30 min at 4uC with 15 ml of
anti-mouse/rat foxp3 antibody conjugated with APC. Cells were
fixed using 500 ml of 0.5% paraformaldehyde solution (p-
formaldehyde 2.5 g and NaCl 4.2 g) and 10.000 cells were
analyzed by flow cytometry. Results were expressed as the
percentage of surface CD4 and CD25 markers and foxp3 in total
lymphocytes.
Measurement of Cytokine Production
The resuspended splenocytes (26106 cells/ml) were stimulated
in 2.5 mg/ml anti CD3 mAb-coated plates and incubated for three
days at 37uC under 5% CO2 and 95% air. Cells were harvested
from 6-well culture plates and the supernatant medium was stored
at 220uC. The amounts of cytokines in splenocytes culture media
were measured by commercial semi-quantitative cytokine anti-
body array (QuantibodyR Mouse Cytokine Array I, QAM-CYT-1,
from Ray Biotech, Inc., Atlanta, GA, USA) following the
manufacture’s protocol. 100 ml of sample was used for each
condition.
Statistical Analysis
The results are expressed as the mean of n values 6 standard
deviation. Plasma samples were assayed in duplicate. Significant
differences were established by the unpaired t-test, using the
computer program GraphPad InStat (GraphPad Software V2.03).
When the variance was not homogeneous, a non-parametric test
was performed (Mann-Whitney). The level of statistical signifi-
cance was set at P,0.05.
Results
Food Consumption and Body Weight Evolution
CT and BWF1 (SLE) mice showed a healthy appearance
throughout the study. No death from unexpected causes or due to
ethical euthanasia was recorded in either group. From the
beginning of the study up to week 16, SLE mice consumed
a higher amount (x1.18 fold, Figure 1A) of solid food than CT
mice. Accordingly, during the same time period SLE mice showed
a higher body weight (x1.18 fold, Figure 1B) than CT animals.
Markers of Systemic Lupus Erythematosus
The plasma anti-ds-DNA antibody concentration rose steadily
in SLE mice in comparison with CT animals, from a 61.3 fold
increase at week 8 to a63.5 fold increase at week 36 (Figure 2A).
SLE mice consistently showed a modest reduction (between
60.81–x0.90 fold vs CT values) in the percentage of CD4+ T cells
in spleen lymphocytes (Figure 2B). Despite this reduction, the
percentage of CD4+CD25+ T cells was increased at week 8 (x1.4
fold vs CT values, Figure 2C), and the percentage of
CD4+CD25+FoxP3 T cells increased in SLE mice at week 8
(x1.4 fold vs CT values) and 16 (x1.16 fold vs CT values)
(Figure 2D).
Cytokine production by splenocytes was measured at week 8,
16, 24 and 36. The concentration of almost every cytokine in the
supernatant of splenocytes from both SLE and CT mice increased
throughout the study, except for granulocyte macrophage-colony
stimulating factor (GM-CSF), interleukin (IL) -3, IL-12, IL-17,
keratinocyte-derived cytokine (KC), and monocyte chemotactic
protein-1 (MCP-1) (data not shown). At week 36, the concentra-
tions of IL-2 (x2.3 fold, Figure 3A), IL-17 (x4.4 fold, Figure 3B),
and MCP-1 (x3.2 fold, Figure 3C) were higher in samples from
SLE mice than CT ones, while the concentrations of IL-4 (x0.47
fold, Figure 3D), IL-5 (x0.46 fold, Figure 3E), IL-10 (x0.18 fold,
Figure 3F), IL-13 (x0.16 fold, Figure 3G), monocyte/macrophages
colony stimulating factor (M-CSF) (x0.49 fold, Figure 3H), tumor
necrosis factor a (TNFa) (x0.58 fold, Figure 3I), and vascular
endothelial growth factor (VEGF) (x0.33 fold, Figure 3J) were
lower in samples from SLE mice.
Figure 4. Plot of individual 24 h proteinuria values, expressed as arbitrary units, for control (C) and BWF1 mice (L) at weeks 20, 24
and 32.
doi:10.1371/journal.pone.0051118.g004
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Renal function abruptly worsened in SLE mice by the end of
the study. While plasma creatinine concentrations did not vary
along the study (data not shown), 24 h proteinuria was higher in
SLE than in CT mice by week 32 (Figure 4). In agreement,
analysis of H&E-stained kidney sections obtained at week 36
showed a higher inflammation and glomerular hypercellularity
score in tissue samples from SLE than from CT mice (Figure 5).
Markers of Metabolic Syndrome
SLE mice showed hepatic steatosis at weeks 8 and 16 (x1.5 fold
vs CT for liver triglyceride content), which disappeared at later
time points (Figure 6A), with no change in hepatic fatty acid b-
oxidation activity (data not shown). Of the several plasma analytes
measured (triglycerides, NEFA, glucose, leptin and insulin) only
leptin and insulin concentrations were changed in SLE vs CT mice
(Figure 6B and 6C). SLE mice were hyperleptinemic at weeks 8
and 16 (x3.1 and 62.1 fold vs CT, respectively), and hyperinsu-
linemic throughout the entire study (x2.2 fold vs CT, at week 16
the difference was not significant). Furthermore, the ratio between
visceral adipose tissue and body weight was higher in SLE than in
CT mice, although the difference progressively decreased
throughout the study, from an increase of61.83 fold at week 8,
to a61.17 fold at week 24, with no significant difference at the end
of the study (week 36) (Figure 6D). Despite the hyperleptinemia,
livers of 16-week-old SLE animals had no increased levels of P-
Tyr-STAT3 protein (Figure 6E), a marker of leptin activity. As
Figure 5. BFWF1 mice, aged 36 weeks, showed increased kidney pathology. Hystological analysis of individual inflammatory (A) and
glomerular hypercellularity scores (B) for CT and SLE mice, evaluated as described in the Material and Methods section. Representative photographs
of renal sections from control (CT) (C) and BWF1 (SLE) (D,E) mice at the age of 36 weeks (H&E staining, light microscopy, original magnification640).
Arrows indicate mesangial glomerular proliferation (D) and cellular extracapillary half-moon (E).
doi:10.1371/journal.pone.0051118.g005
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Figure 6. Bar diagrams showing hepatic triglyceride content (A), plasma leptin (B), and insulin concentrations (C), and percentage
of adipose visceral tissue (D), expressed as the mean6sd of 8 animals, for control and SLE mice at the weeks of sacrifice. E. Bar
diagrams showing the relative amount of P-Tyr-STAT-3 protein in liver tissue, expressed as the mean 6 sd of values from 8 animals, from control (CT)
and BWF1 (SLE) mice. The amount of protein loaded was confirmed by the Bradford method, and the uniformity of protein loading in each lane was
assessed by determining the signal of b–actin as a control-loading protein.* P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0051118.g006
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maximal differences in the MS between SLE and CT mice
clustered around week 16, at this time point we used a commercial
PCR Array to characterize the expression of 85 genes involved in
insulin signaling in liver and visceral adipose tissue samples. In the
liver, 12 genes were down-regulated and 1 gene was up-regulated
in SLE vs CT mice, while in visceral adipose tissue, 23 genes were
down-regulated and 1 gene was up-regulated in SLE vs CT mice
(Tables 1 and 2). Of all these genes, only pck2 (phosphoenolpir-
uvate carboxykinase 2) and rps6k (ribosomal protein serine 6
kinase) were similarly down-regulated in both tissues. We selected
some key genes in order to elucidate whether changes in mRNA
were translated into similar alterations in protein levels. Thus, we
determined the amount of total Akt (thymoma viral proto
oncogen), IRS-1 (insulin receptor substrate-1), and RPS6K protein
in visceral adipose tissue samples, as well as PPARc(peroxisome
proliferator activated receptor c), FRAP1 (FK506 binding protein
Figure 7. Bar diagrams showing the levels of AKT (A), IRS-1 (B) and RPS6K (C) protein in adipose tissue, and PPARc (D), mTOR (E),
and RPS6K (F) protein in liver tissue, expressed as the mean 6 sd of values from 8 animals aged 16 weeks, for control (CT) and
BWF1 (SLE) mice. The amount of protein loaded was confirmed by the Bradford method, and the uniformity of protein loading in each lane was
assessed by determining the signal of b–actin as a control-loading protein. A representative autoradiography from a Western blot determination of
two animals per group is shown. # P= 0.05, * P,0.05, ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0051118.g007
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12-rapamycin associated protein 1 or mTOR –mammalian target
of rapamycin), and also RPS6K protein in liver samples. The
expression of all these proteins was markedly reduced in samples
from SLE vs CT (Figure 7), except in the case of mTOR
(Figure 7e), which was increased63.04 fold in liver samples from
SLE vs CT, in sharp contrast with the reduction in its specific
mRNA levels.
Discussion
Here we used a murine model of SLE (the BWF1 mouse),
which, like humans with this autoimmune disease, shows the
classical manifestations of MS. Our results indicate that these
metabolic alterations temporally precede the development of lupus
symptoms in this model.
Thus, from the beginning of the study until week 16, SLE mice
showed clear signs of metabolic alterations that temporally
preceded the development of lupus symptoms, such as hyperpha-
gia, hyperleptinemia, hyperinsulinemia, fatty liver and increased
visceral adipose tissue. During this period, anti-dsDNA antibody
plasma levels were low, and no clear signs of lupus disease were
observed. By the end of the study, metabolic disturbances had
almost disappeared, except for the increased levels of plasma
insulin. Coincident in time with the waning of metabolic
alterations, anti-dsDNA antibody reached maximal levels and
manifestations of lupus nephritis appeared, exemplified by pro-
teinuria (week 32) and a higher inflammation score and
glomerular hypercellularity in renal tissue samples from SLE mice
(week 36). Also at week 36, the profile of cytokine production by
stimulated splenocytes from these mice was consistent with
autoimmunity promotion, with an increased production of type
Th1 (IL-2) and Th17 (IL-17) cell cytokines, and fundamentally,
a reduced production of type Th2 cell cytokines (IL-4, IL-5, IL-10,
and IL-3) [19–22]. In a similar study using the same model,
Alperovich et al. [23] reported the appearance of lupus-related
signs earlier, and mortality was higher than in the present study.
Thus, the authors reported a 69% survival rate at week 36, with
high plasma anti-dsDNA antibody levels from week 20 and
proteinuria from week 28. In our study, survival at week 36 was
100%, with animals showing a marked increase in plasma anti-
dsDNA antibody levels at week 24 and proteinuria at week 32.
Although we do not know the reason for this discrepancy in the
severity of the evolution of lupus manifestations, in our case the
metabolic disturbances preceded the appearance of the clinical
symptoms of SLE. Once the autoimmune disease flourished, the
deep alteration of whole body homeostasis may have obliterated
the signs of diseased metabolism, such as the increase in
triglyceride accretion in liver or adipose visceral tissue.
The development of autoimmune diseases is promoted by
deficiency in a special set of regulatory T cells that are crucial in
the maintenance of autologous tolerance and are characterized by
the expression of CD4, CD25 and FoxP3 (CD4+CD25+FoxP3+
Tregs) [24]. It has been described that leptin, an adipocytokine
derived from body fat stores, reduces the proliferation of Tregs
[25–27]. However, in our study SLE mice were hyperleptinemic at
weeks 8 and 16, while at the same time points they showed
increased proportions of natural or splenic Tregs. The observation
that Tregs did not decrease suggests a deficit of leptin action on the
proliferation of these cells.
Resistance to leptin action in the central nervous system and
peripheral organs, such as the liver, has been reported in rodent
experimental models and in humans [28,29]. Although Ryan et al.
[15] described that hyperleptinemic BWF1 mice showed no signs
of central leptin resistance, their results did not ruled out the
possibility of peripheral leptin resistance. To explore this issue, we
determined the amount of signal transducer and activator of
transcription 3 (STAT3) protein phosphorylated on tyrosine (P-
Tyr-STAT3), a marker of leptin receptor activation [30]. We did
not detect differences in the amount of P-Tyr-STAT3 in liver
samples of SLE or CT animals obtained at week 16 (Figure 6E).
This observation confirms leptin resistance in peripheral tissues. It
could be hypothesized that young SLE mice are protected from
the development of the clinical symptoms of SLE by the increased
production of Tregs, which occurs because of peripheral leptin
resistance.
As SLE mice also showed mildly elevated plasma insulin
concentrations during the entire study, we addressed whether
these animals also developed insulin resistance in the liver or
visceral adipose tissue. Using a commercial cDNA array specif-
ically designed to determine the expression of genes involved in
insulin signaling, we demonstrated a marked reduction in the
expression of key genes directly participating in the transmission of
this signal in the visceral adipose tissue of SLE mice at week 16. Of
the 24 genes modified, 10 genes directly involved in insulin
signaling (Akt1, Akt3, Frs3, Gab1, Igf1r, Irs1, Nck1, Pik3r2, Prkcz, and
Slc2a1) were down-regulated. This finding points to insulin
resistance in the visceral adipose tissue of SLE mice and suggests
Table 1. Genes whose expression was altered in livers from
16-week old SLE vs CT mice.
Gene Name
Fold
change 95% CI P
Dok1 Docking protein 1 0.64 0.46–0.82 0.030
Dusp14 Dual specificity
phosphatase 14
0.82 0.74–0.89 0.017
Eif2b1 Eukaryotic translation
initiation
factor 2B, subunit 1
(alpha)
0.23 0.00–0.67 0.019
Eif4ebp1 Eukaryotic translation
initiation
factor 4E binding
protein 1
0.02 0.00–0.11 0.010
Frap1 FK506 binding protein
12-
rapamycin associated
protein 1
0.56 0.42–0.70 0.005
Gpd1 Glycerol-3-phosphate
dehydrogenase 1
(soluble)
0.70 0.49–0.90 0.044
Hras1 Harvey rat sarcoma virus
oncogene 1
4.78 3.80–5.77 0.000
Lep Leptin 0.38 0.19–0.58 0.014
Pck2 Phosphoenolpyruvate
carboxykinase 2
(mitochondrial)
0.54 0.36–0.72 0.022
PPARg Peroxisome proliferator
activated receptor
gamma
0.57 0.46–0.68 0.002
Raf1 V-raf-leukemia viral
oncogene 1
0.61 0.43–0.80 0.015
Rps6ka1 Ribosomal protein S6
kinase
polypeptide 1
0.65 0.50–0.81 0.015
Klf10 Kruppel-like factor 10 0.43 0.25–0.61 0.015
doi:10.1371/journal.pone.0051118.t001
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that this resistance is responsible for the increase in insulin plasma
concentrations detected in these animals. The down-regulation of
Akt, and Irs1, genes coding for two essential proteins in the
intracellular transmission pathway of the insulin receptor [31], was
confirmed at the protein level.
When we applied the same commercial cDNA array to hepatic
samples, the expression of the above mentioned genes was not
modified; instead, we detected a marked down-regulation of
Eif2b1, Eif4ebp1, and Rps6ka1 in the livers of 16-week-old SLE
mice. Proteins coded by these genes are downstream of the
signaling pathway of the mTORC1 complex, which is involved in
cell growth, translation, and ribosomal protein synthesis [32].
Moreover, the mTORC1 complex is formed by two main
components, the proteins Raptor and mTOR [32], the latter
coded by Frap1, which was also down-regulated in the livers of
SLE mice. When we attempted to confirm these results at the
protein level, although liver Rps6ka1 protein (S6kinase) was
reduced, the amount of mTOR protein was markedly increased.
The reason for this discrepancy remains unknown. One can
speculate that the mTORC1 system was over-stimulated in the
livers of SLE mice. This may elicit a cellular compensatory
response in an attempt to decrease the over-activity of the system
by down-regulating the mRNA expression of its main components,
Eif2b1, Eif4ebp1, and Rps6ka1 and mTOR itself.
Recent data points to an association between the increased
prevalence of several types of cancer in type 2 diabetic patients and
sustained hyperinsulinemia. In this situation, the continuous
activity of insulin in non-resistant tissues promotes the activation
of the mTORC1 system, thereby favoring cellular proliferation
and tumor development [33]. Furthermore, it has been shown that
lupus nephritis in rodent models and humans is directly related to
the activation of the mTOR pathway in renal tissue [34,35]. Also,
drugs that inhibit mTOR activity are effective in the treatment of
SLE manifestations [4,5,23].
As a conclusion, our results indicate that, although metabolic
alterations, mainly leptin resistance in the BWF1 mice, slow-down
the progression of autoimmunity, the presence of hyperinsulinemia
and the sustained insulin stimulation of organs that remain insulin-
sensitive, such as the liver and potentially the kidneys, facilitates
the overexpression and activity of the mTOR system and the
appearance of the clinical symptoms of SLE. As the whole body
homeostasis deteriorates, metabolic symptoms, except for increases
in plasma insulin concentrations, decline and disappear, while
classical SLE symptoms progressively develop. If these findings can
be extrapolated to humans, subclinical insulin resistance, sustained
over time, could be the key factor for the development of clinical
SLE in subjects with an autoimmune-prone genetic background.
Table 2. Genes whose expression was altered in visceral adipose tissue from 16-week old SLE vs CT mice.
Gene Name Fold change 95% CI P
Acaca Acetyl-Coenzyme A carboxylase alpha 0.07 0.00–0.27 0.029
Aebp1 AE binding protein 1 0.01 0.00–0.03 0.036
Akt1 Thymoma viral proto-oncogene 1 0.07 0.00–0.20 0.026
Akt3 Thymoma viral proto-oncogene 3 0.11 0.00–0.43 0.027
Araf V-raf murine sarcoma 3611 viral oncogene
homolog
0.18 0.00–0.46 0.046
Bcl2l1 Bcl2-like 1 0.10 0.00–0.37 0.010
Fbp1 Fructose bisphosphatase 1 0.47 0.24–0.70 0.027
Frs3 Fibroblast growth factor receptor substrate 3 0.10 0.00–0.35 0.034
Gab1 Growth factor receptor bound protein
2-associated protein 1
0.11 0.00–0.34 0.031
Grb10 Growth factor receptor bound protein 10 1.70 1.44–1.96 0.003
Igf1r Insulin-like growth factor I receptor 0.05 0.02–0.09 0.010
Irs1 Insulin receptor substrate 1 0.33 0.10–0.57 0.028
Jun Jun oncogene 0.07 0.00–0.17 0.028
Mapk1 Mitogen-activated protein kinase 1 0.29 0.04–0.54 0.048
Nck1 Non-catalytic region of tyrosine kinase adaptor protein 10.43 0.09–0.76 0.050
Pck2 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.16 0.00–0.32 0.004
Pik3r2 Phosphatidylinositol 3-kinase, regulatory subunit,
polypeptide 2 (p85 beta)
0.07 0.00–0.24 0.023
Ppp1ca Protein phosphatase 1, catalytic subunit, alpha isoform 0.08 0.00–0.26 0.015
Prkcz Protein kinase C, zeta 0.26 0.00–0.55 0.004
Ptpn1 Protein tyrosine phosphatase, non-receptor type 1 0.04 0.00–0.13 0.001
Retn Resistin 0.20 0.00–0.52 0.023
Rps6ka1 Ribosomal protein S6 kinase polypeptide 1 0.07 0.00–0.21 0.011
Slc27a4 Solute carrier family 27 (fatty acid transporter),
member 4
0.09 0.00–0.27 0.045
Slc2a1 Solute carrier family 2 (facilitated glucose
transporter), member 1
0.05 0.00–0.13 0.008
doi:10.1371/journal.pone.0051118.t002
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